Orfosbuvir - Nanjing Sanhome Pharmaceutical
Latest Information Update: 16 Jul 2024
At a glance
- Originator Nanjing Sanhome Pharmaceutical
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hepatitis C
Most Recent Events
- 10 Jun 2024 Phase-III clinical trials in Hepatitis C before June 2024 (unspecified route) (Nanjing Sanhome Pharmaceutical pipeline, June 2024)